QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)

Exelixis (EXEL) Stock Forecast, Price & News

$19.28
+0.27 (+1.42%)
(As of 05/31/2023 ET)
Compare
Today's Range
$19.00
$19.38
50-Day Range
$18.17
$20.48
52-Week Range
$14.87
$22.47
Volume
3.43 million shs
Average Volume
2.96 million shs
Market Capitalization
$6.28 billion
P/E Ratio
40.17
Dividend Yield
N/A
Price Target
$25.33

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
31.5% Upside
$25.33 Price Target
Short Interest
Healthy
2.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.37mentions of Exelixis in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$2.37 M Sold Last Quarter
Proj. Earnings Growth
50.77%
From $0.65 to $0.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.08 out of 5 stars

Medical Sector

23rd out of 1,006 stocks

Biological Products, Except Diagnostic Industry

4th out of 167 stocks


EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (EXEL)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Stifel Nicolaus Sticks to Their Hold Rating for Exelixis (EXEL)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Exelixis: If It Ain't Broke...
Exelixis Inc EXEL Stock Quote
Exelixis (NASDAQ: EXEL)
RBC Capital Keeps Their Buy Rating on Exelixis (EXEL)
Exelixis: Q1 Earnings Snapshot
Exelixis (EXEL) Receives a New Rating from Piper Sandler
8 Analysts Have This to Say About Exelixis
Exelixis (EXEL) Q1 2023 Earnings Call Transcript
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
2/07/2023
Today
5/31/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
1,223
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$25.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+31.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$182.28 million
Pretax Margin
11.86%

Debt

Sales & Book Value

Annual Sales
$1.61 billion
Cash Flow
$0.63 per share
Book Value
$7.85 per share

Miscellaneous

Free Float
316,158,000
Market Cap
$6.28 billion
Optionable
Optionable
Beta
0.68

Social Links


Key Executives

  • Michael M. MorrisseyMichael M. Morrissey
    President, Chief Executive Officer & Director
  • Christopher J. SennerChristopher J. Senner
    Chief Financial Officer & Executive Vice President
  • Dana Aftab
    Chief Scientific Officer & Executive VP-Discovery
  • Vicki L. Goodman
    Chief Medical Officer & Executive Vice President
  • Jeffrey J. HessekielJeffrey J. Hessekiel
    Secretary, Executive VP & General Counsel













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price forecast for 2023?

8 equities research analysts have issued 1 year target prices for Exelixis' stock. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they expect the company's stock price to reach $25.33 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2023?

Exelixis' stock was trading at $16.04 at the beginning of the year. Since then, EXEL stock has increased by 18.5% and is now trading at $19.01.
View the best growth stocks for 2023 here
.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,410,000 shares, an increase of 21.5% from the April 30th total of 6,100,000 shares. Based on an average trading volume of 3,050,000 shares, the days-to-cover ratio is currently 2.4 days.
View Exelixis' Short Interest
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our EXEL earnings forecast
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) announced its earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.04. The biotechnology company had revenue of $423.92 million for the quarter, compared to the consensus estimate of $418.71 million. Exelixis had a trailing twelve-month return on equity of 6.20% and a net margin of 9.24%. The company's quarterly revenue was down 6.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 EPS.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.77 billion-$1.88 billion, compared to the consensus revenue estimate of $1.83 billion.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.14%), Farallon Capital Management LLC (7.22%), Renaissance Technologies LLC (4.70%), State Street Corp (3.98%), JPMorgan Chase & Co. (2.38%) and Price T Rowe Associates Inc. MD (1.85%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $19.01.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.19 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 1,223 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -